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Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known
to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be
rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine
development is underway. We review the current status of antiviral therapies focusing on RNA viruses,
highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to
accelerate drug discovery efforts.
Introduction
Viruses, and in particular, RNA viruses, dominate the World
Health Organisation (WHO)’s current list of ten global health
threats. The list includes AIDS caused by the Human Immuno-
deficiency virus (HIV), a global influenza pandemic, Dengue
virus (DENV), and viral diseases caused by the Ebola virus
(EBOV) and other high threat pathogens: various haemorrhagic
fevers, Zika virus (ZIKV), Nipah virus, Middle Eastern Respiratory
Syndrome coronavirus (MERS-CoV), Severe Acute Respiratory Syn-
drome coronavirus (SARS-CoV-1) and Disease X (‘‘an unknown
pathogen that could cause a serious epidemic’’).1 Today Disease
X is unquestionably COVID-19, caused by SARS-CoV-2, a corona-
virus closely related to SARS-CoV-1 that almost certainly emerged
as a zoonosis from horseshoe bats in China.2,3 While planning for
an influenza pandemic is an ongoing global priority, the 2014
EBOV disease (EBVD) outbreak in West Africa and the emergence
in 2015 of ZIKV-caused diseases in Brazil that spread rapidly to 84
countries around the world are a stark warning of the potential
threat and the lack of preparedness for dealing with RNA virus
outbreaks.4–6 The SARS-CoV-2/COVID-19 pandemic has further
exposed the lack of antiviral compounds that can be rapidly
mobilized and deployed for the treatment of re-emerging or
emerging viral diseases.7 Here we review the current status of
antiviral therapies, highlighting strategies for combatting EBOV-
causing disease (EBOD) and COVID-19, targets for antiviral drug
discovery and discuss the challenges, solutions and options to
accelerate antiviral drug discovery efforts.
Antiviral strategies
The development of antiviral therapies requires a fundamental
understanding of the chemical biology of the virus and in
particular its interaction with the host cell. As obligate para-
sites, all viruses are dependent on the cellular processes of their
host cells and as such, share the basic features of their
infectious lifecycle. For the purposes of this review the focus
will be on EBOV and SARS-CoV-2 representing negative () and
positive (+) sense single-stranded RNA viruses, respectively (Fig. 1).
The strategies for combatting viral diseases are prevention
(vaccines) and treatment (antiviral drugs and antibodies). More
than 220 viruses are known to infect humans, 80% of which are
naturally persistent in animals.15 In September 2019 there was
a total of 87 clinically approved vaccines against 14 human
viruses (mostly for influenza).16,17 The time ‘‘normally’’
required for the successful development of a vaccine against
any disease be it bacterial, parasitic or viral is usually between
3 and 10 years and in many cases, longer. Not all vaccines that
elicit protection against infection prove to be successful. The
licenced Dengue fever vaccine, Dengvaxias, led to antibody-
dependent enhancement (ADE) of infection by different DENV
serotypes in vaccinated patients18 and ZIKV vaccines have also
been unsuccessful due to ADE. However, a significant mile-
stone was reached in December 2019, when the US FDA
approved the first EBOV vaccine that was extensively deployed to
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suppress a major EBVD outbreak in the Democratic Republic of the
Congo (DRC).19 Still, while the first EBVD vaccine trials in primates
had already begun in 2000, it took the 2014 West African outbreak
to galvanize a global effort to develop an effective vaccine.
The declaration of COVID-19 as a Public Health Emergency of
International Concern on January 30, 2020 has been followed by
an unprecedented mobilisation of global resources to develop a
protective vaccine for SARS-CoV-2, building on experience gained
from the SARS-CoV-1 and MERS-CoV epidemics.20,21 However,
developing a safe, effective vaccine for a rapidly-emerging, highly
virulent novel pathogen like SARS-CoV-2, to stem a global pan-
demic is extremely challenging.22 Furthermore, producing the
4 5.6 billion doses of a single dose vaccine to establish
COVID-19 herd immunity world-wide will require an unpre-
cedented, coordinated effort.
In the absence of an effective vaccine, the availability of safe
and effective treatments is critically important in the early
stages of an emerging, highly pathogenic, viral outbreak. The
isolation and identification of neutralizing antibodies from blood
samples donated by recovered patients provides opportunities for
refining vaccine design and the development of antibody therapies,
including neutralizing monoclonal antibodies and nanobodies
(therapeutic proteins based on single-domain antibody fragments),
for the treatment of COVID-19.23,24 There are numerous, mono-
clonal antibody therapies, including LyCoV555 (Eli Lilly) and
REGN-COV2 (Regeneron) in clinical trials. But while early data
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show promise, the success of antibody therapies for SARS-CoV-2
will depend upon overcoming resistance through mutations in the
S protein and the potential problem of ADE.24
Antiviral drug development can be considered a success
story, but currently for only 10 human viral pathogens with
almost half of these compounds being antiretrovirals.16,17
Typically the paucity of antiviral drugs stems from the fact that
a number of key criteria are required to be met before substantial
funding is invested into drug development programmes. First,
there must be sufficient medical need, chiefly influenced by high
disease incidence and severity. Investment can be influenced by
the availability and effectiveness of a vaccine (although effective
vaccine availability does not always preclude antiviral develop-
ment). There must be sufficient technical knowhow and knowl-
edge about the target virus to facilitate antiviral drug
development. Importantly, economic incentives driven by high
development costs and market value render diseases with a long
duration, more financially attractive targets. It is thus no coin-
cidence that the majority of clinically approved antiviral drugs
target viruses that cause persistent and/or latent infections
e.g. herpes viruses, HIV, Hepatitis C Virus (HCV) and Hepatitis
B Virus. Influenza viruses, which cause acute respiratory infec-
tions, are the key exception. However, the threat posed by
influenza pandemics is ever present and anti-influenza drugs
are stockpiled by individual governments as part of their pan-
demic preparedness plans.4 Thus, with the exception of
HIV/AIDS, Influenza and now COVID-19, most of the viral
diseases on the WHO list of global health threats can be
considered to be ‘‘neglected viral diseases’’.25
Antiviral drugs and targets
The SARS-CoV-2 pandemic has brought the need for antiviral
drug development into sharp focus, not only to respond to the
current global health crisis but also to prepare for future
outbreaks caused by other viruses for which antiviral drugs
are unavailable. Antiviral drug development can be steered by
building upon existing successful strategies. This section will
review key antiviral targets that have led to clinically approved
antivirals, using examples against herpes, HIV, HCV and influ-
enza viruses and how these successful strategies can be applied
to SARS-CoV-2 and EBOV drug discovery. The key drug classes
discussed primarily target the entry, replication, proteolytic
processing and particle egress steps of the infectious virus
lifecycle (Fig. 1).
Most approved antiviral drugs target a viral enzyme that
plays an essential role in virus replication.16 Viral (DNA or RNA)
polymerases are highly successful drug targets. Polymerase inhi-
bitors can be divided into two broad classes (i) nucleos(t)ide
analogues and (ii) non-nucleos(t)ide allosteric inhibitors. Allosteric
inhibitors bind the polymerase, but not at the catalytic active site,
causing conformational changes that impair polymerase
function.16 Examples include the HIV non-nucleoside reverse
transcriptase inhibitors (NNRTIs), the most recent to obtain FDA
approval being doravirine 1 (Fig. 2). Nucleos(t)ide analogue inhi-
bitors are chemically synthesized purine and pyrimidine deriva-
tives with chemical alterations in base or sugar components that
abrogate the growing nucleotide chain during replication.16 AZT
(azidothymidine) 2 (Fig. 2), the first anti-HIV nucleoside reverse
Fig. 1 The infectious lifecycles of EBOV and SARS-CoV-2. EBOV binding
to host cells occurs via interaction between the viral glycoproteins (GPs)
and C-type lectins and cellular phosphatidylserine (PtdSer) receptors that
interact with PtdSer in the viral envelope. The virus enters host cells by
macropinocytosis and is trafficked through early and late endosomes,
where acidification triggers fusion and uncoating followed by synthesis of
the (+) genome and its release into thecytoplasm.8,9 EBOV replicates in
cytoplasmic inclusion bodies.10 Using the host cell machinery, viral mRNAs
encoding the GPs are translated into the endoplasmic reticulum (ER) and
trafficked to the cell surface. Nucleocapsid proteins and non-structural
proteins required for (+) RNA synthesis during infection, are translated
in the cytoplasm and assembly of particles occurs at the cell surface.11
SARS-CoV-1 and likely SARS-CoV-2 binding and entry involves interaction
between the virus surface spike (S) protein and the host angiotensin-
converting enzyme 2 (ACE2) receptor. Proteolytic cleavage by host serine
proteases mediates entry via endocytosis12 and the virus is trafficked
within endosomes until fusion with mature lysosomes. This results in
SARS-CoV-2 uncoating, fusion and release of the (+) RNA genome into
the cytoplasm13 followed by translation of the viral replicase. Replication
likely occurs in association with membrane-bound vesicles derived from
the ER. mRNAs are translated into viral polyproteins that are cleaved into
structural and non-structural proteins by viral proteases (3CLpro, also
known as the main protease, Mpro, and PLpro).14 Assembly occurs in the
intermediate compartment between the ER and Golgi with packaged
virions transported to the cell surface and released via exocytosis to infect
new cells.12
Fig. 2 Representative examples of polymerase and protease inhibitors
highlighted in this review.
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transcriptase inhibitor (NRTI), is a thymidine analogue that con-
tains an azide group in place of the usual nucleoside OH group, to
which subsequent nucleosides cannot bind.16 Nucleos(t)ide
analogue inhibitors are administered as prodrugs, which upon
cell up-take are metabolized by host and/or viral kinases to
their active triphosphate form. Acyclovir 3; an acyclic guanosine
analogue (Fig. 2) used to treat Herpes simplex virus (HSV)
infection, has high selectivity due to specific phosphorylation
by the HSV-encoded thymidine kinase confining activity to
virus-infected cells.16subsequent nucleosides cannot bind.16
Nucleos(t)ide analogue inhibitors are administered as pro-
drugs, which upon cell up-take are metabolized by host and/
or viral kinases to their active triphosphate form. Acyclovir 3; an
acyclic guanosine analogue (Fig. 2) used to treat Herpes simplex
virus (HSV) infection, has high selectivity due to specific
phosphorylation by the HSV-encoded thymidine kinase confin-
ing activity to virus-infected cells.16
Development of an effective antiviral drug is typically followed
by expansion of the successful strategy with numerous chemical
variations providing improvements in parameters including
affinity, pharmacology, toxicity and drug resistance profiles.
Expansion of the successful structure(s) to other viruses beyond
the initial clinical target is also possible, especially for polymerase
inhibitors because all RNA viruses encode an RNA-dependent RNA
polymerase (RdRp). Drugs targeting RdRps may have the capacity
for activity against different viruses for which antiviral drugs are
not currently available. Indeed, remdesivir 4 (Fig. 2), a monopho-
sphate prodrug of a 10-cyano adenosine nucleoside analogue, has
in vitro and in vivo activity against multiple RNA virus families
including filoviruses (EBOV) and coronaviruses (SARS-CoV-1,
SARS-CoV-2, MERS-CoV)26–28 and has recently been granted FDA
emergency use authorization for COVID-19 treatment.29 Another
example of a broadly acting antiviral is the guanosine nucleoside
analogue inhibitor ribavirin.30 Ribavirin 5 (Fig. 2) is often com-
bined with other antiviral agents and is clinically approved
e.g. against HCV, but is also used, unlicensed, against some viral
hemorrhagic fevers.30 Also in this category is Favipiravir
6 (Fig. 2), a prodrug that is ultimately converted to its ribofur-
anosyl 50-triphosphate metabolite (favipiravir-RTP), incorporated
as a pseudopurine by the viral RdRp.25 Favipiravir is clinically
approved in Japan for treating influenza, is also broadly active
in vitro against other RNA viruses including SARS-CoV-1 and
MERS-CoV21 and exhibits potential protective effects against
EBOV in patients with low to moderately high viremia.5,25
Favipiravir is incorporated at high rates resulting in lethal
mutagenesis of SARS-CoV-2 viral RNA during replication
in vitro31 and the compound is currently in clinical trials for
treating COVID-19.
Protease inhibitors are another major class of approved
antiviral drugs developed primarily to treat HIV and then HCV
infections. All approved HIV protease inhibitors are designed
with a peptidomimetic hydroxyethylene scaffold e.g. Saquinavir
7, with the exception of tipranavir 8, which has a coumarin
scaffold (Fig. 2).16 Coronaviruses encode two proteases,
chymotrypsin-like protease (3CLpro, also known as the main
protease Mpro) and papain-like protease (PLpro), which are very
attractive antiviral targets for candidate antiviral molecules,
particularly following the emergence of SARS-CoV-2.32,33 Repur-
posing of HIV-1 protease inhibitors (e.g. Lopinavir/Rotinavir) for
the treatment of Covid-19, has been proposed on the basis of
in vitro and animal model studies showing inhibitory activity
against SARS-CoV-1, SARS-CoV-2 and MERS-CoV by targeting
3CLpro, however clinical trials do not support the use of Lopi-
navir/Ritonavir for the treatment of Covid-19 patients as no
clinical benefit has been observed.34 Following the SARS-CoV-1
and MERS-CoV outbreaks, numerous 3CLpro and PLpro inhibi-
tors have been identified. Whilst these inhibitors have not been
developed clinically, they represent an excellent resource to kick-
start the development of SARS-CoV-2 protease inhibitors, particu-
larly because SARS-CoV-1 and SARS-CoV-2 3CLpro and PLpro share
96% and 83% sequence identity respectively.32,33 Further, It would
be prudent to test candidate protease inhibitors against SARS-like
coronaviruses identified in bats that have zoonotic potential, to
enable the development of pan-coronavirus inhibitors to future
proof against further coronavirus outbreaks. Polymerase inhibitors
likely have greater capacity than protease inhibitors for broadly
acting activity because not all viruses encode a protease; EBOV
lacks a protease and thus protease inhibitors cannot be part of any
future arsenal of anti-EBOV drugs.34
Other viral enzymes have been successfully targeted, but the
resultant drug classes tend to be specific to a particular virus or
related viruses. Important examples are the influenza neura-
minidase (NA) inhibitors, oseltamivir, zanamivir and peramivir,
which are the standard-of-care therapeutic treatment for influ-
enza infection.4 NA inhibitors competitively target the NA active
site, blocking cleavage of sialic acid residues, preventing influ-
enza virus particle egress. In 2018, the first new anti-influenza
drug class in two decades was approved for clinical use. The
first-in-class drug, baloxavir marboxil, targets the polymerase
acidic endonuclease activity of the influenza polymerase
complex, inhibiting the mRNA cap-snatching mechanism.4
The highly conserved coronavirus helicase and the exonuclease
nsp14, which play an essential role in viral RNA synthesis, are
also attractive potential drug targets for SARS-CoV-2.36,37
Entry/fusion inhibitors are an important example of antiviral
drugs that target non-enzymatic viral processes; for example three
very different anti-HIV agents have been approved (i) Enfuvirtide, a
biomimetic peptide that inhibits fusion,16 (ii) Maraviroc, an
antagonist of the host cell co-receptor CCR5 required for HIV
entry16 and (iii) Ibalizumab, a non-immunosuppressive huma-
nized monoclonal antibody that acts as a post attachment inhi-
bitor that binds the host CD4 primary receptor.38 Cocktails of
therapeutic antibodies such as REGN-EB3 are being trialed against
EBOV35 and the search is on for therapeutic antibodies against
SARS-CoV-2.39 SARS-CoV-2 entry requires the S protein, which
recognizes the host cell ACE2 receptor (Fig. 1) and is primed by
host cell proteases (e.g. cathepsin L proteinase, furin, TMPRSS2),
offering multiple potential antiviral strategies,33,40 indeed a clini-
cally proven TMPRSS2 (protease) inhibitor, A1AT, has recently
been shown to block SARS-CoV-2 entry.40
In addition to antiviral drugs that directly target host-virus
interactions, host cell pathways, such as immunomodulatory
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drugs, are being used as indirect antiviral targets. Extensive
discussion of this class of agent is beyond the scope of this
review, but a classic example is interferon (IFN), which
enhances the immune response and elicits an antiviral state.
IFN is clinically approved for use in HCV and HBV infections
and is being trialed in COVID-19 patients and a number of
other immunomodulatory agents are being explored as anti-
COVID-19 strategies.33,36 Importantly, the readily available and
affordable immunosuppressant and anti-inflammatory drug,
dexamethasone, reported by the Oxford University RECOVERY
trial to reduce death in hospitalized COVID-19 patients with
severe respiratory complications,41 is routinely being employed
in patients in intensive care units.
A major challenge facing antiviral drug development is
resistance. Indeed, drug resistance is a commonly reported
issue affecting approved antiviral drugs that directly act against
a viral target or virus-host interaction. Drug resistance is
particularly problematic with respect to RNA viruses due to
the error-prone nature of RdRps, the rapid rate of viral replica-
tion and frequent recombination events. Existing drug classes
are subject to ongoing programs to improve the genetic barrier
to resistance and the availability of drug classes with different
mechanisms of action facilitates salvage or combination therapy.
For example, HIV combination therapy consists of a minimum of
two drugs from different mechanistic classes and typically contains
three of more different drugs. This combination therapy does not
provide a cure thus patients are required to take antivirals for life,
increasing problems associated with drug resistance. Although not
typically as challenging, drug resistance issues have also been
documented for acute infections. Overall, problems with drug
resistance significantly increase costs and time associated with
antiviral drug development, exacerbating a lack of willingness to
invest in neglected viral diseases.
Alternative antiviral strategies that target host cell factors
and/or pathways required for virus replication are widely predicted
to make acquisition of resistance less likely, but the trade-off is
likely to be a higher chance of undesirable side effects.42,43
However this may not be as problematic for acute viral diseases,
such as EBVD and Covid-9 since toxicity is often linked to the
duration of treatment. Approaches targeting common cellular
pathways exploited by multiple viruses offer the potential for
development of broadly-acting antivirals that have activity across
a family of viruses or ideally multiple virus families or viruses with
a similar ‘‘life-style’’ e.g. respiratory viruses. The development of
host-targeted antivirals has lagged behind that of directly-acting
antivirals with very few, such as IFN, approved for clinical use.
Hydroxquinolines are an example of a class of molecules under
development, which like IFN, modulate immune responses to
change infection outcome in favour of the host by activating the
IFN pathway component IRF3.44 Several other host targets are
being investigated for their utility to develop broadly acting
antivirals, including cyclophilins, glucosidase, heat shock proteins,
inosine-50-monphospahte dehydrogenase, eukaryotic initiation
factor 2a and various kinases.42 Ideally, targets should be host
factors that are critical for the replication of several types of viruses
but dispersible for the host. Significant further research is needed
to identify the most appropriate cellular factors, pathways and
processes to target. As discussed above, broadly-acting antivirals
can also be developed against highly conserved viral targets, such
as RdRps, which may have a high natural genetic barrier to drug
resistance; e.g. coronavirus resistance to remdesivir has been
reported, but is associated with an in vitro fitness cost and in vivo
attenuation.45 Thus polymerase inhibitors are likely to be the best
option for developing broad spectrum directly-acting antivirals.
Directing research effort and investment into the develop-
ment of broadly-acting antivirals,46 rather than the contemporary
one-virus-one-drug approach, is urgently needed to tackle the
fact that antivirals are not currently available for hundreds of
viruses that cause human disease and the conundrum of pre-
dicting which deadly virus will be the next to emerge into the
human population. Development of broadly acting antivirals is
very challenging requiring substantial, sustained research invest-
ment. Such an investment would be a shrewd response to the
SARS-CoV-2 pandemic, which has starkly highlighted the impor-
tance of having antiviral drugs that can be rapidly deployed to
treat a newly emerged viral disease.
Approaches to antiviral drug discovery
One of the main technological limitations of antiviral testing on
emerging RNA viruses is the need for biosafety containment
facilities (e.g. SARS-CoV-2 and EBOV require Category 3 and 4
containment levels, respectively). These facilities are expensive
to build, commission and maintain and understandably
require a high level of oversight. As a result, their global
distribution is limited, reducing opportunities for testing com-
pounds against live viruses. A high level of training and skill is
required to ensure safe working inside these facilities and to
prevent accidental infection of researchers and escape of
viruses. It is essential that solutions are sought to these issues
to provide a larger pipeline of potential antiviral candidates.
One option is to use pseudoviruses that are safe to use in
Category 2 facilities. Pseudoviruses are chimeric particles pro-
duced with envelope proteins from the target pathogenic virus
displayed on the surface of a benign carrier virus (e.g. Vesicular
Stomatitis Virus that can be useful for antiviral discovery with
respect to inhibitors that act at entry/fusion steps of virus
replication). Pseudoviruses may utilize the envelope proteins
of the carrier virus for binding and entry, but retain the native
functions required to initiate infection and viral replication of
the target virus, which is detected via the activity of a reporter
gene e.g. luciferase. Viral mini replicons expressing reporter
genes, that do not produce infectious particles, are also alterna-
tives for isolating replication inhibitors. The sensitivity of these
ex vivo systems is particularly useful for screening natural product
extracts to identify potential antiviral candidates to progress to
phenotypic screening with live virus, an approach used by the NIH
National Cancer Institute in the early 1990s with HIV.
Phenotypic screening in host cells, however, reveals a great
deal more about the targets and mechanism of action of assay
compounds compared to high throughput assay technology.


































































































Chem. Soc. Rev. This journal is©The Royal Society of Chemistry 2021
Throughput is being accelerated by improvements in auto-
mated image analysis amongst other approaches. An alterna-
tive approach is to test the effect of compounds in vitro on
target viral proteins to determine if they can inhibit enzymes
such as RdRps and proteases or block key protein–protein
interactions. Recombinant viral proteins can safely be pro-
duced in larger amounts and used in a variety of assays using
biophysical methods such as surface plasmon resonance.
Screening natural products for antiviral activity is particularly
attractive given their biological relevance as well as intrinsic
chemical and structural diversity. One way to introduce more
natural products and/or derivatives into antiviral screening is to
use a virtual screening approach against a number of different
viral proteins. The approach is summarised in Fig. 3, starting
with calculating minimised structures of natural product data-
bases, followed by docking these against crystal structures of
viral proteins. Using docking scores and calculated physico-
chemical parameters allows the prioritisation of compounds
for antiviral assays and crystal soaking experiments to verify
activity and to assess whether the docking calculations were
accurate. The first step is to have a comprehensive database of all
described natural products. Although many open-access and
subscription databases have been created, most focus on specific
types of compounds, or have not been maintained over a number
of years. A recent attempt, ‘COlleCtion of Open NatUral pro-
ducTs’ (COCONUT), contains structures and sparse annotations
for over 400 000 non-redundant natural products.47
The ZINC database,48 containing commercially available
compounds that have been minimised for docking simulations,
has a subset of natural products. Docking of minimised natural
product structures against X-ray structures of target proteins
can be achieved using open source software such as
AutoDock,49 which gives docking scores that can be used to
select the best candidates, although it is good practice to
visually inspect top candidates to check if they actually main-
tain essential interaction with target residues. There are issues
around the conformational flexibility of the compounds
and proteins, but these can be addressed using multiple
conformers of the compounds or a fully flexible docking
approach in which both the compound and protein are treated
dynamically. Docking scores can be complemented by calcu-
lated physicochemical properties and predictions of whether
compounds are likely to be absorbed in the gastrointestinal
tract or whether they cross the blood–brain barrier.50 Care must
also be taken to ensure that binding to the intended active site
is stronger than potential alternative off-target binding sites. A
recent publication reviews existing natural products active
against several coronavirus targets and also presents an exam-
ple of the virtual screening approach above to select natural
products that may inhibit SARS-CoV-2 Mpro and have drug-like
properties.51 A much larger scale effort is ‘deep-docking’ of the
entire 1.3 billion ZINC library against SARS-CoV-2 Mpro, which
gave a list of 1000 chemically diverse, commercially available
compounds that have better docking scores than existing
protease inhibitors.52 Large scale open projects such as the
Covid Moonshot53 are attempting to use a combination of
approaches including crystal structures of Mpro with drug-
like ‘fragments’ to enable crowd-sourced drug design, rapid
synthesis, followed by crystal soaking and structure determina-
tion of the protein–ligand complex and enzyme assays.
Challenges, solutions and options
Given that drug discovery and development is an inherently
lengthy and costly undertaking, this becomes even more apparent
when considering the high attrition rate of compounds during
preclinical research. Furthermore, only three out of ten drugs that
make it to the clinic recover their capital investment.54 Therefore,
an efficient drug discovery pipeline is essential for ensuring
profitability to sustain the business and maintain continued
investment in R&D by the pharmaceutical industry. Furthermore,
agitation for cost containment of drug supplies advocated by
governments, commercial players and civil society activism can
weigh heavily on profit margins. This partly explains why relatively
speaking, infectious disease drug discovery is not prominent in
the innovative pharmaceutical R&D industry. Within the context
of antivirals, drug discovery efforts have targeted viruses that are
economically important in developed countries. However, COVID-
19 has reminded us that an emerging virus can wreck world
economies and significantly disrupt life in unprecedented ways.
As mentioned above, a dearth of clinically approved antivirals,
focussed toward a very limited series of viruses are available. It is
imperative that this precarious situation is addressed. Funding
within the value chain of antiviral drug discovery and develop-
ment, from blue skies research and preclinical drug discovery to
clinical trials, is fragmented. The area of antiviral drug develop-
ment needs to be viewed as a continuum so funding one
component will not suffice and is therefore futile. There is
limited funding of academic research projects targeting
neglected viruses that can replenish the pipeline. Furthermore,
the short-term nature of the funding means that promising
molecules do not progress far along the value chain Thus
funders should coordinate their activities to ensure that there
is appropriate focus on each component of the value chain.
Fig. 3 A possible route for virtual screening of natural product libraries
followed by the prioritisation of hits based on assay, co-crystallisation and
physicochemical data before structural optimisation, preclinical and clin-
ical evaluation can occur.
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For any small molecule drug discovery project regardless of
approach (validated target- or phenotypic whole cell screening-
based), the chemistry starting point is critical. With the same
established screening approach not delivering much, there is an
urgent need to find new sources of starting points. In this regard
underexplored natural product sources provide an opportunity to
find unique biologically-relevant starting points.
Fortunately, it is not all bad news as far as COVID-19 is
concerned. The pandemic is catalysing and promoting colla-
boration and innovation in R&D between funding bodies from
both the public and private sectors. An example of this is the
COVID-19 Therapeutics Accelerator, first announced by the Bill
and Melinda Gates Foundation (BMGF), which attracted addi-
tional funding from a range of governments, philanthropies
and individuals who would not ordinarily fund infectious
disease research. The second is the announcement of a partner-
ship between the BMGF and 15 Pharma companies who have
committed their expertise and assets to the fight against
COVID-19. Needless to say, these focused efforts on COVID-19
could be a blueprint for preparedness against future outbreaks
of yet-to-be identified or re-emerging infectious agents and
could provide avenues to address unmet medical needs where
an economic/business case for Pharma is absent. Also encouraging
is the agreement between Gilead and Cipla to provide generic
remdesivir at an affordable cost to developing countries e.g. South
Africa.
An innovative pharmaceutical industry should view antivirals
targeting neglected viruses as an opportunity to address an unmet
medical need of public health significance. In addition, they
present the opportunity to boost the pipeline of new medicines,
given that the chances of discovering a novel druggable target are
greater in this field, relative to the more widely explored thera-
peutic areas. A novel druggable target identified from a neglected
virus could have a human equivalent in a lucrative therapeutic
area where there are attractive commercial returns.55 Furthermore,
collaborations between industry and academia in a precompetitive
space would facilitate mutually beneficial sharing of knowledge in
innovative strategies for improving drug discovery efficiency.56
The announcement of a partnership between the BMGF and 15
Pharma companies who have committed their expertise and
assets to the fight against COVID-19 are excellent examples of this.
COVID-19 has been a real wake-up call particularly in Africa
and has exposed the fundamental limitations of many sectors.
The devastation caused by the 2014 EBVD outbreak is still fresh
in people’s minds. With sporadic outbreaks still being reported
in countries like the DRC, there is genuine fear that COVID-19
will exacerbate the situation. The impact of COVID-19 on other
infectious agents, e.g. those responsible for Ebola, malaria,
tuberculosis and HIV/AIDS (and vice versa), is bringing renewed
focus on the importance of not neglecting endemic infectious
diseases given the risk of shifting resources away from other
longstanding endemic diseases to fighting COVID-19. Historically,
pharmaceutical R&D has mostly occurred in high-income coun-
tries, where technology, infrastructure and a critical mass of skilled
scientists and clinicians are available. There is an urgent need for
Africans to build drug discovery and development capacity in close
proximity to African patient populations. For any developed vaccine
or drug to benefit the African patient population in terms of
treatment outcomes, there is therefore an urgent need to increase
the number of clinical trials happening in Africa and the number
of Africans enrolled into clinical trials. Amongst other interven-
tions, this would require African governments to insist on local
clinical trial data before a product can be licensed in their country.
To make this a reality, there needs to be increased support for
building capacity in clinical research.
From a resource mobilization perspective in Africa, Ebola
has provided the necessary blueprint in view of the inequalities
and high poverty levels on the continent. The 2014 outbreak
exposed the poor health systems in West Africa, whose failure
contributed to more deaths. COVID-19 has offered opportunities
for funders, including Foundations and High Net Worth Indivi-
duals, to be innovative and collaborative even as they partner
with governments to provide continent-specific solutions. For
example, during the 2014 Ebola crisis a fund was set up through
the African Union to fight the pandemic. Individuals as well as
philanthropies could donate money through digital platforms
and banking innovations.
Fexinidazole, the first oral treatment for African sleeping
sickness, provides an excellent example for the antiviral field.
During a search for compounds with anti-parasitic activity in
2005, the not-for-profit Drugs for Neglected Diseases initiative
(DNDi,) in collaboration with the Swiss Tropical and Public
Health Institute, rediscovered fexinidazole, a drug previously
abandoned by its pharmaceutical industry developer, Hoechst
(now Sanofi) in the 1980s. A formal partnership between the
DNDi and Sanofi led to the development and subsequent
approval of fexinidazole by the European Medicines Agency
for the treatment of African sleeping sickness.by The drug is
currently in use in the Democratic Republic of Congo.
Conclusions
SARS-CoV-2/COVID-19 pandemic has underscored the critical
need for antiviral compounds that can be rapidly deployed
when a previously neglected or new virus is abruptly catapulted
to global emergency status. The one-virus-one-drug approach to
antiviral discovery and development has been successful, but
only if the viral disease satisfies the medical and economic
criteria required to drive the substantial research effort, financial
investment and political will, essential for delivering an effective
clinically approved antiviral drug. The global campaign to find
SARS-CoV-2 antivirals will undoubtedly result in the develop-
ment innovative approaches to screening, accelerated clinical
testing and rapid manufacturing scale-up to bring these com-
pounds to the market as quickly as possible.
Are we prepared for the next viral pandemic? The answer is
still ‘‘no’’. The catastrophic impact of the SARS-CoV-2 pandemic
has the potential to divert attention away from other viruses that
cause human disease and have the potential to cause the next
pandemic. To mitigate this risk, there needs to be continued
surveillance and modelling to support the prediction of which
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deadly virus will be the next to emerge into the human popula-
tion. Of critical importance is directing research effort and
investment into the development of broadly-acting antivirals
that can be mobilised as the first line of defence upon emergence
of new viral pathogens.
Developing antivirals to treat emerging viral diseases will
require consideration of new consortium models, including
public-private partnerships, exemplified by the product develop-
ment partnership, DNDi, as well as open and precompetitive
consortia models. The open consortium model would involve
joint collaboration between the pharmaceutical industry, academic
and public-funded organizations whose defining features would
include consortium members collectively sharing the funding
burden, resources and expertise. Alternatively, the precompetitive
consortium model would involve industry partners, who ordinarily
would be commercial competitors, and other non-industry part-
ners in multidisciplinary collaborative research. Several precompe-
titive consortia have been formed in specialized healthcare-related
sectors, including the recently established Bill and Melinda Gates
Foundation-supported Tuberculosis Drug Accelerator, a ground-
breaking partnership between several Pharma companies, a bio-
tech, research institutions and a prescription drug plan that seeks
to develop a new TB drug regimen through collaboration in early-
stage drug discovery research. Other examples include the Struc-
tural Genomics Consortium and Innovative Medicines Initiative.
The aforementioned approaches would have greater impact on
antiviral drug discovery efforts and efficiency than the currently
fragmented venture.
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